Skip to content

Air Tamponade and Non-supine Positioning in Macular Hole Surgery.

Air Tamponade and Non-supine Positioning in Macular Hole Surgery. A Randomized Controlled Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03572725
Enrollment
150
Registered
2018-06-28
Start date
2018-09-26
Completion date
2021-05-28
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Holes

Brief summary

This is a prospective, multicenter, randomized non-inferiority trial, where the macular hole closure rate with intraocular air tamponade is compared to the closure rate with gas tamponade.The patients are randomized to receive either air or gas (26% SF6) as intraocular tamponade, just prior to the intraocular flushing of the tamponade during the vitrectomy procedure. Postoperatively, the patients adhere to the nonsupine regimen for three days, and the tennis ball technique is used during sleep to enhance patients' positioning compliance.

Interventions

PROCEDUREGas tamponade

Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.

PROCEDUREAir tamponade

Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.

Sponsors

Haukeland University Hospital
CollaboratorOTHER
Trondheim University Hospital
CollaboratorOTHER
University Hospital of North Norway
CollaboratorOTHER
Oslo University Hospital
CollaboratorOTHER
Helse Stavanger HF
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primary macular hole ≤ 400 μm * Duration no more than 24 months * Able to sign informed content * Signed informed content

Exclusion criteria

* Earlier vitreoretinal surgery in present eye * Secondary macular holes caused by other conditions than vitreomacular traction * Myopic macular hole, i.e. excessive myopia (more than -6 dioptres) * Posttraumatic macular hole * Macular holes secondary to retinal detachment or other retinal diseases * Surgery under general anesthesia * Visual acuity below 20/40 in fellow-eye

Design outcomes

Primary

MeasureTime frameDescription
Macular hole closure verified on OCT2 - 8 weeks postoperativelyMacular hole closure verified on OCT after one macular hole intervention

Secondary

MeasureTime frameDescription
Closure of macular holes ≤ 250 µm2 - 8 weeks postoperativelyMacular hole closure verified on OCT after one macular hole intervention
Closure of macular holes >250 µm and ≤ 400 µm2 - 8 weeks postoperativelyMacular hole closure verified on OCT after one macular hole intervention
Intraocular pressureFirst postoperative dayStandard procedure for assessment of intraocular pressure
Visual acuity2 - 8 weeks postoperativelyStandard procedure for assessment of visual acuity

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026